Earthworm Populations in a Wheat-Soybean Double-Crop System under Seven Years of Established Residue Management Practices

Earthworms improve soil structure, distribute litter and microbes, stimulate microbial activity, facilitate decomposition, and increase nitrogen (N) availability for plant growth. Earthworm density is often reduced in low organic matter soils that are intensively managed to grow row crops. This study was designed to relate earthworm density and community composition to residue management after seven years of established management practices in a wheat (Triticum aestivum L.)-soybean (Glycine max (L.) Merr.) double-crop system maintained in Marianna, AR. Residue management practices included conventional tillage (CT) and no-tillage (NT), N fertilization to produce high and low wheat residue amounts left in the field, and burning and non-burning of residue after wheat harvest. Total earthworm densities ranged from 271 to 508 m-2 across treatments. Both exotic Aporrectodea trapezoides (Duges) and native Diplocardia sylvicola (Gates) adult earthworms were present with very little difference in diversity among sampled communities; however, more than 50 % of adults were D. sylvicola in all treatments. Residue level and burning influenced total, juvenile, and native earthworm densities differently in CT and NT. Native, total, or juvenile earthworm densities in different treatment combinations were related to soil properties, including pH, electrical conductivity, and Mehlich-III- K, Mn, Mg, Cu, S and Ca concentrations. Native earthworms predominated with a common exotic species in a wheat-soybean double-crop system in Arkansas with residue management practices interacting to impact the density of earthworms

Maternal Cognitions and Depressive Symptoms during the Perinatal Period.

This dissertation consists of three separate longitudinal studies that examined the relations between maternal cognitions and maternal depressive symptoms during the perinatal period. The goal of the first study was to develop and validate a new measure, the Rigidity of Maternal Beliefs Scale (RMBS), which explored maternal self-efficacy, child vulnerability, and perceptions of societal expectations of mothers. A community sample of 134 women completed the measure once during pregnancy and once during the first 3 months postpartum. Exploratory factor analysis identified a four-factor solution best fit the data, with two of the three hypothesized factors emerging. Analyses revealed that the measure was reliable, valid, and that the prenatal RMBS predicted postpartum depressive symptoms. The purpose of the second study was to test bidirectional and unidirectional models of depressive symptoms and parenting stress in a sample of 105 women over the first 14 months postpartum. Three specific domains of parenting stress were also examined: difficult child stress, parental distress, and parent-child dysfunctional interaction (PCDI) stress. Structural equation modeling revealed different patterns, depending on the type of stress. For total parenting stress, the hypothesized unidirectional model of stress predicting depressive symptoms fit best, whereas for difficult child stress, the alternative unidirectional model of depressive symptoms predicting stress fit best. Neither the unidirectional or bidirectional models were a good fit for parental distress. The hypothesized bidirectional model of PCDI and depressive symptoms was a good fit. The objective of the third study was to investigate the associations of depressive symptoms, maternal self-efficacy, and rumination for 231 second-time mothers during the perinatal period. Bidirectional effects of depressive symptoms and maternal self-efficacy were also examined and rumination tested as a moderating factor. Despite significant correlations between the study variables, structural equation modeling revealed no significant paths between depressive symptoms and maternal self-efficacy. Additionally, rumination level was not found to be a moderating factor. Findings from these three studies suggest that maternal cognitions and depressive symptoms are related. Future research should explore the specific nature of the associations, which may help researchers and clinicians to design more effective interventions for women struggling with perinatal depression.PHDSocial Work and PsychologyUniversity of Michigan, Horace H. Rackham School of Graduate Studieshttp://deepblue.lib.umich.edu/bitstream/2027.42/100001/1/lizzyb_1.pd

Are Women'S Parenting‐Specific Beliefs Associated With Depressive Symptoms In The Perinatal Period? Development Of The Rigidity Of Maternal Beliefs Scale

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/110632/1/da22280.pd

Individual Variation in Fathers’ Testosterone Reactivity to Infant Distress Predicts Parenting Behaviors with their 1-Year-Old Infants

Positive father involvement is associated with positive child outcomes. There is great variation in fathers’ involvement and fathering behaviors, and men’s testosterone (T) has been proposed as a potential biological contributor to paternal involvement. Previous studies investigating testosterone changes in response to father-infant interactions or exposure to infant cues are unclear as to whether individual variation in T is predictive of fathering behavior. We show that individual variation in fathers’ T reactivity to their infants during a challenging laboratory paradigm (Strange Situation) uniquely predicted fathers’ positive parenting behaviors during a subsequent father-infant interaction, in addition to other psychosocial determinants of paternal involvement, such as dispositional empathy and marital quality. The findings have implications for understanding fathering behaviors and how fathers can contribute to their children’s socioemotional development

Comparative Study of Intravaginal Metronidazole and Triple-Sulfa Therapy for Bacterial Vaginosis

Objective: We sought to compare the efficacy of metronidazole gel vs. triple-sulfa cream in the treatment of bacterial vaginosis (BV)

Behavioral Coping Phenotypes and Associated Psychosocial Outcomes of Pregnant and Postpartum Women During the COVID-19 Pandemic

The impact of COVID-19-related stress on perinatal women is of heightened public health concern given the established intergenerational impact of maternal stress-exposure on infants and fetuses. There is urgent need to characterize the coping styles associated with adverse psychosocial outcomes in perinatal women during the COVID-19 pandemic to help mitigate the potential for lasting sequelae on both mothers and infants. This study uses a data-driven approach to identify the patterns of behavioral coping strategies that associate with maternal psychosocial distress during the COVID-19 pandemic in a large multicenter sample of pregnant women (N = 2876) and postpartum women (N = 1536). Data was collected from 9 states across the United States from March to October 2020. Women reported behaviors they were engaging in to manage pandemic-related stress, symptoms of depression, anxiety and global psychological distress, as well as changes in energy levels, sleep quality and stress levels. Using latent profile analysis, we identified four behavioral phenotypes of coping strategies. Critically, phenotypes with high levels of passive coping strategies (increased screen time, social media, and intake of comfort foods) were associated with elevated symptoms of depression, anxiety, and global psychological distress, as well as worsening stress and energy levels, relative to other coping phenotypes. In contrast, phenotypes with high levels of active coping strategies (social support, and self-care) were associated with greater resiliency relative to other phenotypes. The identification of these widespread coping phenotypes reveals novel behavioral patterns associated with risk and resiliency to pandemic-related stress in perinatal women. These findings may contribute to early identification of women at risk for poor long-term outcomes and indicate malleable targets for interventions aimed at mitigating lasting sequelae on women and children during the COVID-19 pandemic

Activation of the dopamine 1 and dopamine 5 receptors increase skeletal muscle mass and force production under non-atrophying and atrophying conditions

<p>Abstract</p> <p>Background</p> <p>Control of skeletal muscle mass and force production is a complex physiological process involving numerous regulatory systems. Agents that increase skeletal muscle cAMP levels have been shown to modulate skeletal muscle mass and force production. The dopamine 1 receptor and its closely related homolog, the dopamine 5 receptor, are G-protein coupled receptors that are expressed in skeletal muscle and increase cAMP levels when activated. Thus we hypothesize that activation of the dopamine 1 and/or 5 receptor will increase skeletal muscle cAMP levels thereby modulating skeletal muscle mass and force production.</p> <p>Methods</p> <p>We treated isolated mouse tibialis anterior (TA) and medial gastrocnemius (MG) muscles in tissue bath with the selective dopamine 1 receptor and dopamine 5 receptor agonist SKF 81297 to determine if activation of skeletal muscle dopamine 1 and dopamine 5 receptors will increase cAMP. We dosed wild-type mice, dopamine 1 receptor knockout mice and dopamine 5 receptor knockout mice undergoing casting-induced disuse atrophy with SKF 81297 to determine if activation of the dopamine 1 and dopamine 5 receptors results in hypertrophy of non-atrophying skeletal muscle and preservation of atrophying skeletal muscle mass and force production.</p> <p>Results</p> <p>In tissue bath, isolated mouse TA and MG muscles responded to SKF 81297 treatment with increased cAMP levels. Treating wild-type mice with SKF 81297 reduced casting-induced TA and MG muscle mass loss in addition to increasing the mass of non-atrophying TA and MG muscles. In dopamine 1 receptor knockout mice, extensor digitorum longus (EDL) and soleus muscle mass and force was not preserved during casting with SKF 81297 treatment, in contrast to significant preservation of casted wild-type mouse EDL and soleus mass and EDL force with SKF 81297 treatment. Dosing dopamine 5 receptor knockout mice with SKF 81297 did not significantly preserve EDL and soleus muscle mass and force although wild-type mouse EDL mass and force was significantly preserved SKF 81297 treatment.</p> <p>Conclusions</p> <p>These data demonstrate for the first time that treatment with a dopamine 1/5 receptor agonist results in (1) significant preservation of EDL, TA, MG and soleus muscle mass and EDL muscle force production during periods of atrophy and (2) hypertrophy of TA and MG muscle. These effects appear to be mainly mediated by both the dopamine 1 and dopamine 5 receptors.</p

Examination of ozonesonde data for trends and trend changes incorporating solar and Arctic oscillation signals

One major question that arises with the implementation of the Montreal Protocol and its subsequent conventions is our ability to determine that an ozone “recovery” is in process. Toward this we have utilized a statistical model suggested by Reinsel et al. (2002) that utilizes the idea of a trend and a trend change at a specific time and applied it to 12 ozonesonde stations in the midlatitudes of the Northern Hemisphere. The lower stratosphere, in particular, is of significance as this is where the ozone concentration is a maximum and also where heterogeneous ozone losses have been noted. This statistical methodology suffers, however, from the ambiguities of having to select a specific time for the ozone trend to change and the fact that the Mt Pinatubo volcanic aerosols impacted the ozone amount. Within this paper, we analyze the ozonesonde station data utilizing the above model but examine the statistical stability of the computed results by allowing the point of inflection to change from 1995 through 2000 and also exclude varying amounts of data from the post-Pinatubo period. The results indicate that while the impacts of deleting data and changing the inflection point are nontrivial, the overall results are consistent in that there has been a major change in the ozone trend in the time frame of 1996 and that a reasonable scenario is to utilize a change point in 1996 and exclude 2 years of data after the 1991 Mt. Pinatubo eruption. In addition, we include a term for the Arctic oscillation within the statistical model and demonstrate that it is statistically significant

Co-trimoxazole or multivitamin multimineral supplement for post-discharge outcomes after severe anaemia in African children: a randomised controlled trial

Background Severe anaemia is a leading cause of paediatric admission to hospital in Africa; post-discharge outcomes remain poor, with high 6-month mortality (8%) and re-admission (17%). We aimed to investigate post-discharge interventions that might improve outcomes. Methods Within the two-stratum, open-label, multicentre, factorial randomised TRACT trial, children aged 2 months to 12 years with severe anaemia, defined as haemoglobin of less than 6 g/dL, at admission to hospital (three in Uganda, one in Malawi) were randomly assigned, using sequentially numbered envelopes linked to a second nonsequentially numbered set of allocations stratified by centre and severity, to enhanced nutritional supplementation with iron and folate-containing multivitamin multimineral supplements versus iron and folate alone at treatment doses (usual care), and to co-trimoxazole versus no co-trimoxazole. All interventions were administered orally and were given for 3 months after discharge from hospital. Separately reported randomisations investigated transfusion management. The primary outcome was 180-day mortality. All analyses were done in the intention-to-treat population; follow-up was 180 days. This trial is registered with the International Standard Randomised Controlled Trial registry, ISRCTN84086586, and follow-up is complete. Findings From Sept 17, 2014, to May 15, 2017, 3983 eligible children were randomly assigned to treatment, and followed up for 180 days. 164 (4%) were lost to follow-up. 1901 (95%) of 1997 assigned multivitamin multimineral supplement, 1911 (96%) of 1986 assigned iron and folate, and 1922 (96%) of 1994 assigned co-trimoxazole started treatment. By day 180, 166 (8%) children in the multivitamin multimineral supplement group versus 169 (9%) children in the iron and folate group had died (hazard ratio [HR] 0·97, 95% CI 0·79–1·21; p=0·81) and 172 (9%) who received co-trimoxazole versus 163 (8%) who did not receive co-trimoxazole had died (HR 1·07, 95% CI 0·86–1·32; p=0·56). We found no evidence of interactions between these randomisations or with transfusion randomisations (p>0·2). By day 180, 489 (24%) children in the multivitamin multimineral supplement group versus 509 (26%) children in the iron and folate group (HR 0·95, 95% CI 0·84–1·07; p=0·40), and 500 (25%) children in the co-trimoxazole group versus 498 (25%) children in the no co-trimoxazole group (1·01, 0·89–1·15; p=0·85) had had one or more serious adverse events. Most serious adverse events were re-admissions, occurring in 692 (17%) children (175 [4%] with at least two re-admissions). Interpretation Neither enhanced supplementation with multivitamin multimineral supplement versus iron and folate treatment or co-trimoxazole prophylaxis improved 6-month survival. High rates of hospital re-admission suggest that novel interventions are urgently required for severe anaemia, given the burden it places on overstretched health services in Africa

Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

BACKGROUND: Cohort studies in adults with HIV showed that dolutegravir was associated with neuropsychiatric adverse events and sleep problems, yet data are scarce in children and adolescents. We aimed to evaluate neuropsychiatric manifestations in children and adolescents treated with dolutegravir-based treatment versus alternative antiretroviral therapy. METHODS: This is a secondary analysis of ODYSSEY, an open-label, multicentre, randomised, non-inferiority trial, in which adolescents and children initiating first-line or second-line antiretroviral therapy were randomly assigned 1:1 to dolutegravir-based treatment or standard-of-care treatment. We assessed neuropsychiatric adverse events (reported by clinicians) and responses to the mood and sleep questionnaires (reported by the participant or their carer) in both groups. We compared the proportions of patients with neuropsychiatric adverse events (neurological, psychiatric, and total), time to first neuropsychiatric adverse event, and participant-reported responses to questionnaires capturing issues with mood, suicidal thoughts, and sleep problems. FINDINGS: Between Sept 20, 2016, and June 22, 2018, 707 participants were enrolled, of whom 345 (49%) were female and 362 (51%) were male, and 623 (88%) were Black-African. Of 707 participants, 350 (50%) were randomly assigned to dolutegravir-based antiretroviral therapy and 357 (50%) to non-dolutegravir-based standard-of-care. 311 (44%) of 707 participants started first-line antiretroviral therapy (ODYSSEY-A; 145 [92%] of 157 participants had efavirenz-based therapy in the standard-of-care group), and 396 (56%) of 707 started second-line therapy (ODYSSEY-B; 195 [98%] of 200 had protease inhibitor-based therapy in the standard-of-care group). During follow-up (median 142 weeks, IQR 124–159), 23 participants had 31 neuropsychiatric adverse events (15 in the dolutegravir group and eight in the standard-of-care group; difference in proportion of participants with ≥1 event p=0·13). 11 participants had one or more neurological events (six and five; p=0·74) and 14 participants had one or more psychiatric events (ten and four; p=0·097). Among 14 participants with psychiatric events, eight participants in the dolutegravir group and four in standard-of-care group had suicidal ideation or behaviour. More participants in the dolutegravir group than the standard-of-care group reported symptoms of self-harm (eight vs one; p=0·025), life not worth living (17 vs five; p=0·0091), or suicidal thoughts (13 vs none; p=0·0006) at one or more follow-up visits. Most reports were transient. There were no differences by treatment group in low mood or feeling sad, problems concentrating, feeling worried or feeling angry or aggressive, sleep problems, or sleep quality. INTERPRETATION: The numbers of neuropsychiatric adverse events and reported neuropsychiatric symptoms were low. However, numerically more participants had psychiatric events and reported suicidality ideation in the dolutegravir group than the standard-of-care group. These differences should be interpreted with caution in an open-label trial. Clinicians and policy makers should consider including suicidality screening of children or adolescents receiving dolutegravir